发布求助
文献互助 智能选刊 最新文献

对 "免疫检查点抑制剂治疗癌症患者的乙型肝炎功能性治愈：一种前景广阔的策略？"和 "肝细胞癌患者是免疫检查点抑制剂治疗乙型肝炎的理想研究人群 "的回复

IF 26.8 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Journal of Hepatology Pub Date : 2024-11-08 DOI:10.1016/j.jhep.2024.10.045
Hsien-Chen Mon, Yi-Hsiang Huang
{"title":"对 \"免疫检查点抑制剂治疗癌症患者的乙型肝炎功能性治愈：一种前景广阔的策略？\"和 \"肝细胞癌患者是免疫检查点抑制剂治疗乙型肝炎的理想研究人群 \"的回复","authors":"Hsien-Chen Mon, Yi-Hsiang Huang","doi":"10.1016/j.jhep.2024.10.045","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial disclosure funding</h2>No financial support was received for this letter.</section></section><section><section><h2>Funding funding</h2>None</section></section><section><section><h2>Conflict-of-interest statement COI</h2>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</section></section><section><section><h2>Author contributions author-disclosure</h2>HCM: manuscript drafting; YHH: critical expert review and revision of the manuscript.</section></section><section><section><h2>Acknowledgements</h2>There are no additional acknowledgements.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"29 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reply to “Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: a promising strategy?” and “Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B”\",\"authors\":\"Hsien-Chen Mon, Yi-Hsiang Huang\",\"doi\":\"10.1016/j.jhep.2024.10.045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>Financial disclosure funding</h2>No financial support was received for this letter.</section></section><section><section><h2>Funding funding</h2>None</section></section><section><section><h2>Conflict-of-interest statement COI</h2>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</section></section><section><section><h2>Author contributions author-disclosure</h2>HCM: manuscript drafting; YHH: critical expert review and revision of the manuscript.</section></section><section><section><h2>Acknowledgements</h2>There are no additional acknowledgements.</section></section>\",\"PeriodicalId\":15888,\"journal\":{\"name\":\"Journal of Hepatology\",\"volume\":\"29 1\",\"pages\":\"\"},\"PeriodicalIF\":26.8000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jhep.2024.10.045\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.10.045","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

章节片段财务披露资助本信件未收到任何财务支持。资助资助无利益冲突声明作者声明他们没有已知的竞争性财务利益或个人关系，这些利益或关系可能会影响本文所报告的工作。作者贡献作者披露HCM：手稿起草；YHH：关键专家评审和手稿修改。致谢无其他致谢。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
分享
查看原文 本刊更多论文
Reply to “Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: a promising strategy?” and “Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B”

Section snippets

Financial disclosure funding

No financial support was received for this letter.

Funding funding

None

Conflict-of-interest statement COI

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Author contributions author-disclosure

HCM: manuscript drafting; YHH: critical expert review and revision of the manuscript.

Acknowledgements

There are no additional acknowledgements.
求助全文
通过发布文献求助，成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Hepatology
Journal of Hepatology 医学-胃肠肝病学
CiteScore
46.10
自引率
4.30%
发文量
2325
审稿时长
30 days
期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信